Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis

Kenji Oritani, Kohshi Ohishi, Shinichiro Okamoto, Keita Kirito, Norio Komatsu, Tetsuzo Tauchi, Hiroshi Handa, Shigeki Saito, Katsuto Takenaka, Kazuya Shimoda, Hikaru Okada, Taro Amagasaki, Shiho Wakase, Kojiro Shimozuma, Koichi Akashi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: Myelofibrosis (MF) is associated with a significant symptom burden that severely impacts patient quality-of-life (QoL). Ruxolitinib, a potent Janus kinase 1 (JAK1)/JAK2 inhibitor, led to substantial improvements in splenomegaly, MF-associated symptoms, and QoL in the phase 3 COMFORT studies, proving superior to placebo and best available therapy. This study evaluated the effect of ruxolitinib on symptoms and QoL in Japanese patients with MF. Methods: A pooled analysis of studies A2202 (NCT01392443) and AJP01 (NCT02087059) of ruxolitinib in Japanese patients with MF (n=81) was conducted. Changes in total symptom score (TSS) and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 were summarized. Results: Most patients received a starting dose of 15 or 20mg twice daily (BID) and had a final titrated dose of ≥10mg BID. Overall, 67.7% (44/65) achieved a ≥50% reduction from baseline in TSS at week 24. Reductions in TSS were seen in every dose group; the greatest reductions occurred in patients with a final titrated dose of 20 or 25mg BID. Improvements in QoL were seen in patients who achieved a ≥50% reduction in TSS. Generally, improvements in TSS and individual symptoms correlated with reductions in spleen size, with those having a ≥35% reduction in spleen volume having the greatest improvements. Conclusions: Consistent with COMFORT-I, ruxolitinib provided substantial improvements in symptoms and QoL in Japanese patients with MF, with higher doses of ruxolitinib associated with better responses.

Original languageEnglish
Pages (from-to)531-537
Number of pages7
JournalCurrent Medical Research and Opinion
Volume34
Issue number3
DOIs
Publication statusPublished - Jan 4 2018

Fingerprint

Primary Myelofibrosis
Quality of Life
Therapeutics
Janus Kinase 1
Spleen
Splenomegaly
INCB018424
Placebos

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis. / Oritani, Kenji; Ohishi, Kohshi; Okamoto, Shinichiro; Kirito, Keita; Komatsu, Norio; Tauchi, Tetsuzo; Handa, Hiroshi; Saito, Shigeki; Takenaka, Katsuto; Shimoda, Kazuya; Okada, Hikaru; Amagasaki, Taro; Wakase, Shiho; Shimozuma, Kojiro; Akashi, Koichi.

In: Current Medical Research and Opinion, Vol. 34, No. 3, 04.01.2018, p. 531-537.

Research output: Contribution to journalArticle

Oritani, K, Ohishi, K, Okamoto, S, Kirito, K, Komatsu, N, Tauchi, T, Handa, H, Saito, S, Takenaka, K, Shimoda, K, Okada, H, Amagasaki, T, Wakase, S, Shimozuma, K & Akashi, K 2018, 'Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis', Current Medical Research and Opinion, vol. 34, no. 3, pp. 531-537. https://doi.org/10.1080/03007995.2017.1415874
Oritani, Kenji ; Ohishi, Kohshi ; Okamoto, Shinichiro ; Kirito, Keita ; Komatsu, Norio ; Tauchi, Tetsuzo ; Handa, Hiroshi ; Saito, Shigeki ; Takenaka, Katsuto ; Shimoda, Kazuya ; Okada, Hikaru ; Amagasaki, Taro ; Wakase, Shiho ; Shimozuma, Kojiro ; Akashi, Koichi. / Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis. In: Current Medical Research and Opinion. 2018 ; Vol. 34, No. 3. pp. 531-537.
@article{25b014ede5344f2a9349029db88fccd8,
title = "Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis",
abstract = "Objectives: Myelofibrosis (MF) is associated with a significant symptom burden that severely impacts patient quality-of-life (QoL). Ruxolitinib, a potent Janus kinase 1 (JAK1)/JAK2 inhibitor, led to substantial improvements in splenomegaly, MF-associated symptoms, and QoL in the phase 3 COMFORT studies, proving superior to placebo and best available therapy. This study evaluated the effect of ruxolitinib on symptoms and QoL in Japanese patients with MF. Methods: A pooled analysis of studies A2202 (NCT01392443) and AJP01 (NCT02087059) of ruxolitinib in Japanese patients with MF (n=81) was conducted. Changes in total symptom score (TSS) and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 were summarized. Results: Most patients received a starting dose of 15 or 20mg twice daily (BID) and had a final titrated dose of ≥10mg BID. Overall, 67.7{\%} (44/65) achieved a ≥50{\%} reduction from baseline in TSS at week 24. Reductions in TSS were seen in every dose group; the greatest reductions occurred in patients with a final titrated dose of 20 or 25mg BID. Improvements in QoL were seen in patients who achieved a ≥50{\%} reduction in TSS. Generally, improvements in TSS and individual symptoms correlated with reductions in spleen size, with those having a ≥35{\%} reduction in spleen volume having the greatest improvements. Conclusions: Consistent with COMFORT-I, ruxolitinib provided substantial improvements in symptoms and QoL in Japanese patients with MF, with higher doses of ruxolitinib associated with better responses.",
author = "Kenji Oritani and Kohshi Ohishi and Shinichiro Okamoto and Keita Kirito and Norio Komatsu and Tetsuzo Tauchi and Hiroshi Handa and Shigeki Saito and Katsuto Takenaka and Kazuya Shimoda and Hikaru Okada and Taro Amagasaki and Shiho Wakase and Kojiro Shimozuma and Koichi Akashi",
year = "2018",
month = "1",
day = "4",
doi = "10.1080/03007995.2017.1415874",
language = "English",
volume = "34",
pages = "531--537",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis

AU - Oritani, Kenji

AU - Ohishi, Kohshi

AU - Okamoto, Shinichiro

AU - Kirito, Keita

AU - Komatsu, Norio

AU - Tauchi, Tetsuzo

AU - Handa, Hiroshi

AU - Saito, Shigeki

AU - Takenaka, Katsuto

AU - Shimoda, Kazuya

AU - Okada, Hikaru

AU - Amagasaki, Taro

AU - Wakase, Shiho

AU - Shimozuma, Kojiro

AU - Akashi, Koichi

PY - 2018/1/4

Y1 - 2018/1/4

N2 - Objectives: Myelofibrosis (MF) is associated with a significant symptom burden that severely impacts patient quality-of-life (QoL). Ruxolitinib, a potent Janus kinase 1 (JAK1)/JAK2 inhibitor, led to substantial improvements in splenomegaly, MF-associated symptoms, and QoL in the phase 3 COMFORT studies, proving superior to placebo and best available therapy. This study evaluated the effect of ruxolitinib on symptoms and QoL in Japanese patients with MF. Methods: A pooled analysis of studies A2202 (NCT01392443) and AJP01 (NCT02087059) of ruxolitinib in Japanese patients with MF (n=81) was conducted. Changes in total symptom score (TSS) and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 were summarized. Results: Most patients received a starting dose of 15 or 20mg twice daily (BID) and had a final titrated dose of ≥10mg BID. Overall, 67.7% (44/65) achieved a ≥50% reduction from baseline in TSS at week 24. Reductions in TSS were seen in every dose group; the greatest reductions occurred in patients with a final titrated dose of 20 or 25mg BID. Improvements in QoL were seen in patients who achieved a ≥50% reduction in TSS. Generally, improvements in TSS and individual symptoms correlated with reductions in spleen size, with those having a ≥35% reduction in spleen volume having the greatest improvements. Conclusions: Consistent with COMFORT-I, ruxolitinib provided substantial improvements in symptoms and QoL in Japanese patients with MF, with higher doses of ruxolitinib associated with better responses.

AB - Objectives: Myelofibrosis (MF) is associated with a significant symptom burden that severely impacts patient quality-of-life (QoL). Ruxolitinib, a potent Janus kinase 1 (JAK1)/JAK2 inhibitor, led to substantial improvements in splenomegaly, MF-associated symptoms, and QoL in the phase 3 COMFORT studies, proving superior to placebo and best available therapy. This study evaluated the effect of ruxolitinib on symptoms and QoL in Japanese patients with MF. Methods: A pooled analysis of studies A2202 (NCT01392443) and AJP01 (NCT02087059) of ruxolitinib in Japanese patients with MF (n=81) was conducted. Changes in total symptom score (TSS) and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 were summarized. Results: Most patients received a starting dose of 15 or 20mg twice daily (BID) and had a final titrated dose of ≥10mg BID. Overall, 67.7% (44/65) achieved a ≥50% reduction from baseline in TSS at week 24. Reductions in TSS were seen in every dose group; the greatest reductions occurred in patients with a final titrated dose of 20 or 25mg BID. Improvements in QoL were seen in patients who achieved a ≥50% reduction in TSS. Generally, improvements in TSS and individual symptoms correlated with reductions in spleen size, with those having a ≥35% reduction in spleen volume having the greatest improvements. Conclusions: Consistent with COMFORT-I, ruxolitinib provided substantial improvements in symptoms and QoL in Japanese patients with MF, with higher doses of ruxolitinib associated with better responses.

UR - http://www.scopus.com/inward/record.url?scp=85041140370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041140370&partnerID=8YFLogxK

U2 - 10.1080/03007995.2017.1415874

DO - 10.1080/03007995.2017.1415874

M3 - Article

C2 - 29224367

AN - SCOPUS:85041140370

VL - 34

SP - 531

EP - 537

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 3

ER -